Hims & Hers Health is a top growth stock with strong cash flow, no debt, and an innovative AI-powered platform. Learn more on ...

Hims reveals that while swiping left and right have become synonymous with dating culture among younger generations, the vast majority of people, young and old, are still meeting in real life (IRL).

The latest trend in treating hair loss may sound familiar — essentially, it’s a repurposed drug first popularized in the ...

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company ...

Hims & Hers Health ( HIMS 7.49%) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target ...

Is the F.A.A. really ensuring safety by disqualifying pilots who receive a diagnosis or treatment? Troy Merritt, a pilot, ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

Step right up, ladies and gentlemen, and welcome to the hottest new spot in town: The Weight-Loss Casino! Here, you don’t ...

Hims launched in 2017 to sell hair-loss and erectile dysfunction drugs. Patients complete a medical questionnaire, select a ...

But following its start in 2017, Hims & Hers ballooned in size to become a much-watched ... Apostrophe would pull prospective ...

Citigroup reiterated their sell rating on shares of Hims & Hers Health (NYSE:HIMS – Free Report) in a research report report published on Thursday,Benzinga reports. They currently have a $27.00 price ...

Shares of HIMS stock opened at $36.01 on Thursday. Hims & Hers Health has a 12-month low of $11.20 and a 12-month high of $72.98. The firm has a market capitalization of $8.00 billion, a price-to ...